Drug Profile
Research programme: protein tyrosine phosphatase inhibitors - Merck Canada
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck Frosst
- Class
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Endocrine disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Endocrine-disorders in Canada
- 30 Aug 2011 Preclinical development is ongoing in Canada